Nkarta NKTX
NASDAQ NKTX
$2.66 +0.19 (+7.69%)
At close: Aug 21, 2026 · 4:00 PM EDT

Nkarta (NKTX) Change in Accured Expenses (2019 - 2026)

Nkarta (NKTX) posted quarterly Change in Accured Expenses of -$3.9 million for Q1 2026, down 2117.71% year-over-year from $192000.0 in Q1 2025, and down 253.37% quarter-over-quarter from $2.5 million in Q4 2025.

Nkarta (NKTX) Change in Accured Expenses (2019 - 2026) Analysis & Trends

Nkarta's Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$3.9 million for Q1 2026.

  • In Q1 2026, Change in Accured Expenses fell 2117.71% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$1.6 million (down 29.9% YoY), while the FY2025 annual figure was $2.5 million, up 155.11% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at -$3.9 million, down from $2.5 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $4.6 million in Q3 2022, with the low at -$3.9 million in Q1 2026.
  • The 5-year median for Change in Accured Expenses is $192000.0 (2025), against an average of $64705.9.
  • The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses soared 285.08% in 2023, then tumbled 2117.71% in 2026.
  • Nkarta's Change in Accured Expenses stood at -$619000.0 in 2022, then jumped by 196.28% to $596000.0 in 2023, then tumbled by 512.08% to -$2.5 million in 2024, then jumped by 202.85% to $2.5 million in 2025, then plunged by 253.37% to -$3.9 million in 2026.
  • Business Quant data shows NKTX's Change in Accured Expenses at -$3.9 million in Q1 2026, $2.5 million in Q4 2025, and $448000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Nkarta 201.14 Mn 201.14 Mn - 4.59 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 4.59 Mn
Jun 30, 2026 4.59 Mn
Mar 31, 2026 -3.87 Mn
Mar 31, 2026 -3.87 Mn
Dec 31, 2025 2.53 Mn
Dec 31, 2025 2.53 Mn
Sep 30, 2025 448,000.00
Sep 30, 2025 448,000.00
Jun 30, 2025 -703,000.00
Jun 30, 2025 -703,000.00
Mar 31, 2025 192,000.00
Mar 31, 2025 192,000.00
Dec 31, 2024 -2.46 Mn
Dec 31, 2024 -2.46 Mn
Sep 30, 2024 130,000.00
Sep 30, 2024 130,000.00
Jun 30, 2024 900,000.00
Jun 30, 2024 900,000.00
Mar 31, 2024 -3.04 Mn
Mar 31, 2024 -3.04 Mn